TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal cancer (CRC).

Change Tx for spleen enlargement after response on Rux? Taper/stop Rux on progression after 1 y of response?

A patient with myelofibrosis was started on ruxolitinib and experienced an initial improvement in symptoms and a decrease in spleen size from 18 cm to 2 cm below the costal margin (BCM). The patient now presents with an enlarged spleen at 6 cm BCM but still feels well. Should the therapy be changed?

Rux dose for 65 yo, symptomatic high-risk MF, platelet count 35K/µL? Platelet count 70K/µL?

A 65-year-old patient with high-risk myelofibrosis, splenomegaly, normal renal function and disease-related symptomatology is being considered to receive ruxolitinib for the first time. What dose would you initiate in each of the following scenarios (or would you not use it)?

Usual Tx (+/- corticosteroids) for pts w/ asymptomatic MF but w/ anemia?

What treatment would you usually recommend for patients whose MF is asymptomatic but who have anemia?

Initial Tx for 65 yo, int-2, sympt MF, baseline anemia? High-risk MF, anemia develops on Rux: Adjust dose?

Which treatment would you most likely initiate for a 65-year-old patient with intermediate-2 myelofibrosis, splenomegaly and significant disease-related symptomatology who has already received EPO and danazol:

Additional Commentary:

What is the role of iron chelation for patients with MF who have frequent transfusion requirements?

Additional Commentary:

How common is the occurrence of hydroxyurea-related leg ulcers?

Additional Commentary:

Is hydroxyurea considered leukemogenic?

Additional Commentary:

Is there cross-resistance between ruxolitinib and other JAK2 inhibitors?

Additional Faculty Comments:

• Cross-resistance between Rux and other JAK2 inhibitors?
• Is hydroxyurea considered leukemogenic?
• How common is the occurrence of hydroxyurea-related leg ulcers?
• Role of iron chelation for pts with MF and frequent transfusions?

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.

Patterns of Care Data Regarding Ruxolitinib Use in Patients without JAK2 Mutations

Allotransplant in patients with MF?

In what situations, if any, do you recommend allotransplant to patients with MF?